Actively Recruiting
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
Led by OHSU Knight Cancer Institute · Updated on 2026-02-27
150
Participants Needed
1
Research Sites
584 weeks
Total Duration
On this page
Sponsors
O
OHSU Knight Cancer Institute
Lead Sponsor
C
Celgene Corporation
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase II trial studies how well gadolinium and ferumoxytol magnetic resonance imaging (MRI) work in diagnosing patients with abnormalities in the central nervous system. Diagnostic procedures, such as gadolinium and ferumoxytol MRI, may help find and diagnose abnormalities in the central nervous system.
CONDITIONS
Official Title
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have neurological symptoms like headache, loss of consciousness, weakness, cranial nerve problems, or seizures
- Have brain abnormalities seen on imaging, either cancerous or non-cancerous
- Have cancer elsewhere in the body that could affect the brain, such as possible metastasis or vascular issues
- Be able to have MRI without anesthesia
- Be at least 10 years old
- Sign informed consent and HIPAA authorization
- Sexually active women of child-bearing potential must agree to use adequate birth control for at least two months after each study cycle
You will not qualify if you...
- Have signs of uncal herniation like sudden pupil changes, quick motor changes, or rapid loss of consciousness
- Have allergic reactions to iron-based drugs like ferumoxytol or related compounds
- Are pregnant, breastfeeding, or suspect pregnancy
- Have metal implants incompatible with MRI, are severely agitated, or allergic to gadolinium contrast
- Have known iron overload (hemochromatosis) unless ruled out by blood tests
- Have received ferumoxytol within 3 weeks before the study
- Have allergies to three or more different drug classes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
OHSU Knight Cancer Institute
Portland, Oregon, United States, 97239
Actively Recruiting
Research Team
A
Amy E Huddleston, MPA:HA, CCRP
CONTACT
L
Lisa C Muir, MPA:HA, CCRP
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here